Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.65 |
| ▸ | GAPDH | P04406 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | STAT6 | P42226 | 1/20 | 0.65 |
| ▸ | PI4KA | P42356 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.65 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.65 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274492 | 1.00 | ADORA3 (0.65) | ADORA3ADORA1SLC29A1MAPK1SMN1; SMN2 | |
| SCHEMBL14429166 | 0.92 | ALDH1A1 (0.56) | ADORA3ADORA1SLC29A1MAPK1SMN1; SMN2 | |
| SCHEMBL1054240 | 0.85 | SLC29A1 (0.69) | ADORA3ADORA1SLC29A1MAPK1SMN1; SMN2 | |
| SCHEMBL1054238 | 0.85 | SLC29A1 (0.69) | ADORA3ADORA1SLC29A1MAPK1SMN1; SMN2 | |
| SCHEMBL17772332 | 0.85 | SLC29A1 (0.69) | ADORA3ADORA1SLC29A1MAPK1SMN1; SMN2 | |
| SCHEMBL28747306 | 0.82 | SLC29A1 (0.65) | ADORA3ADORA1SLC29A1MAPK1SMN1; SMN2 | |
| SCHEMBL27516785 | 0.82 | SLC29A1 (0.65) | ADORA3ADORA1SLC29A1MAPK1SMN1; SMN2 | |
| SCHEMBL14429168 | 0.82 | ADORA2A (0.48) | ADORA3ADORA1SLC29A1MAPK1SMN1; SMN2 | |
| Adenosine SCHEMBL14812472 | 0.82 | ADORA3 (0.91) | ADORA3ADORA1SLC29A1MAPK1SMN1; SMN2 | |
| SCHEMBL13483668 | 0.81 | ADK (0.58) | SLC29A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | disclosed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | disclosed |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | SIXFOLD BIOSCIENCE LTD (GB) | 2022-11-24 | — | — | US | disclosed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | disclosed |
| WO-2021220053-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-11-04 | — | — | WO | disclosed |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | ADORA3 2078/4885ADORA1 2434/4885SLC29A1 840/4885 |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | ADORA3 2078/4885ADORA1 2434/4885SLC29A1 840/4885 |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | ADORA3 2078/4885ADORA1 2434/4885SLC29A1 840/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | ADORA3 2078/4885ADORA1 2434/4885SLC29A1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.